NCT05780424: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 579 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05780424 |
|---|---|
| Title | A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H3: BRII-196/BRII-198) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 16, 2020 |
| Completion date | June 8, 2021 |
| Required reporting date | June 8, 2022, midnight |
| Actual reporting date | Jan. 8, 2024 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 579 |